SVRA NASDAQ
Savara Inc.
1W: -2.4%
1M: -9.6%
3M: -15.2%
YTD: -19.9%
1Y: +9.7%
3Y: +41.7%
5Y: +264.5%
$4.86
+0.34 (+7.52%)
After Hours: $4.78 (-0.08, -1.65%)
Weekly Expected Move ±6.9%
$4
$4
$4
$5
$5
Credit Risk of going bust: lower than 71% of companies Debt: 3.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.6%), Savara Inc. would be worth roughly what it owes.
Total debt $30.1M against a stock market value of $928.7M.
Distance to default 7.71 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $15.1M (short-term plus half of long-term), stock volatility 53.2%; Altman Z'' -7.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.6%), Savara Inc. would be worth roughly what it owes.
Total debt $30.1M against a stock market value of $928.7M.
Distance to default 7.71 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $15.1M (short-term plus half of long-term), stock volatility 53.2%; Altman Z'' -7.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$928.7M
52W Range3.86-7.01
Volume3,441,276
Avg Volume1,987,587
Beta0.25
Dividend—
Analyst Ratings
Company Info
CEOMatthew Pauls
Employees70
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-28
Websitesavarapharma.com
The Tannery
Yardley, PA 19067
US
Yardley, PA 19067
US
512 614 1848
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Latest News
Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts
Savara (NASDAQ:SVRA) Stock Price Down 5.4% – Here’s What Happened
Brokerages Set Savara Inc. (NASDAQ:SVRA) Price Target at $10.00
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Parker Braden C. | F-InKind | 29,323 | $5.07 | 2026-09-24 |
| Lutz Robert Matthew | A-Award | 35,000 | — | 2026-07-15 |
| Lutz Robert Matthew | A-Award | 70,000 | $5.81 | 2026-07-15 |
| Lowrance David L | M-Exempt | 75,000 | $1.59 | 2026-06-22 |
| Lowrance David L | F-InKind | 21,682 | $5.50 | 2026-06-22 |